StockData
vTv Therapeutics Inc. logo

vTv Therapeutics Inc. (VTVT) stock

VTVTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 11/3062% below fair value
$17.29−0.40 (-2.26%)

Close on Nov 17, 2026Market cap $68.37MP/E –Yield –

vTv Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

vTv Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $28.68M, up 131.4% year over year. For fiscal 2025 it was $17.86M, up 54.7% from the year before. Over ten years it grew -4.1% a year on average. The highest annual figure on record is $44.95M in fiscal 2016.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$17.86M+54.7%
FY2024Dec 31, 2024$11.55M-15.1%
FY2023Dec 31, 2023$13.60M+10.0%
FY2022Dec 31, 2022$12.36M-7.3%
FY2021Dec 31, 2021$13.32M+21.0%
FY2020Dec 31, 2020$11.02M-27.1%
FY2019Dec 31, 2019$15.12M-34.4%
FY2018Dec 31, 2018$23.04M-41.9%
FY2017Dec 31, 2017$39.64M-11.8%
FY2016Dec 31, 2016$44.95M+65.0%
FY2015Dec 31, 2015$27.24M+56.7%
FY2014Dec 31, 2014$17.38M-22.0%
FY2013Dec 31, 2013$22.29M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$8.77M+113.7%
Q1 FY2026Mar 31, 2026$8.98M+217.2%
Q4 FY2025Dec 31, 2025$3.91M+74.9%
Q3 FY2025Sep 30, 2025$7.02M+117.7%
Q2 FY2025Jun 30, 2025$4.10M+19.3%
Q1 FY2025Mar 31, 2025$2.83M+6.8%
Q4 FY2024Dec 31, 2024$2.23M+4.5%
Q3 FY2024Sep 30, 2024$3.22M+14.2%
Q2 FY2024Jun 30, 2024$3.44M-26.7%
Q1 FY2024Mar 31, 2024$2.65M-32.8%
Q4 FY2023Dec 31, 2023$2.14M-46.1%
Q3 FY2023Sep 30, 2023$2.82M-7.6%
Q2 FY2023Jun 30, 2023$4.69M+112.7%
Q1 FY2023Mar 31, 2023$3.94M+25.8%
Q4 FY2022Dec 31, 2022$3.96M-26.6%
Q3 FY2022Sep 30, 2022$3.06M+28.3%
Q2 FY2022Jun 30, 2022$2.21M-9.5%
Q1 FY2022Mar 31, 2022$3.13M+1.0%
Q4 FY2021Dec 31, 2021$5.40M+113.2%
Q3 FY2021Sep 30, 2021$2.38M+34.7%
Q2 FY2021Jun 30, 2021$2.44M-2.9%
Q1 FY2021Mar 31, 2021$3.10M-26.2%
Q4 FY2020Dec 31, 2020$2.53M-42.5%
Q3 FY2020Sep 30, 2020$1.77M-51.7%
Q2 FY2020Jun 30, 2020$2.51M-40.7%
Q1 FY2020Mar 31, 2020$4.20M+49.0%
Q4 FY2019Dec 31, 2019$4.41M+57.4%
Q3 FY2019Sep 30, 2019$3.66M+35.8%
Q2 FY2019Jun 30, 2019$4.23M-50.8%
Q1 FY2019Mar 31, 2019$2.82M-68.4%
Q4 FY2018Dec 31, 2018$2.80M-72.2%
Q3 FY2018Sep 30, 2018$2.70M-70.0%
Q2 FY2018Jun 30, 2018$8.59M-10.7%
Q1 FY2018Mar 31, 2018$8.94M-18.4%
Q4 FY2017Dec 31, 2017$10.07M-9.3%
Q3 FY2017Sep 30, 2017$8.99M-15.5%
Q2 FY2017Jun 30, 2017$9.62M–
Q1 FY2017Mar 31, 2017$10.96M–
Q4 FY2016Dec 31, 2016$11.10M–
Q3 FY2016Sep 30, 2016$10.64M–

More vTv Therapeutics figures

See a number that looks wrong?